Syngene (Services) business headwinds persist
Syngene faces a 16% YoY revenue decline due to reduced offtake from a key biologics client. Management expects H2 recovery but specific client demand timeline remains uncertain.
BIOCON / Q1-FY27 / risks
Keep the risk register visible.
Biocon · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Insulin aspart (Kirsty) formulary access incomplete
While insulin glargine market shares have been steadily growing in the US, insulin aspart (branded Kirsty) is still transitioning from closed-loop networks to commercial payers. The timeline and success of formulary negotiations remains a key variable for H2 growth targets.
Working capital and inventory build for H2 may pressure cash flows
Net debt increased ₹1,100 crore sequentially and working capital rose due to inventory build for expected H2 scale-up. If the anticipated demand acceleration does not materialize, this inventory could become a drag on cash flows.
Tariff risk on Indian pharma products in US
Trump administration announced potential tariffs on pharmaceutical imports. While current US law exempts generics and biosimilars, changes in legislation would impact Biocon's largest and most strategically important market.